| Objective:To compare Pirarubicin efficacy with gemcitabine chemotherapy for preventing recurrence of superficial
bladder cancer, bladder within the foreshore him.Methods:40 cases of patients with superficial bladder cancer based on randomly
divided into treatment group and control group 20 cases, all patients using transurethral bladder tumor transurethral approach, the control
group was treated with gemcitabine treatment group were Pirarubicinintravesical different recurrence rate of two groups were compared.Results:All patients completed treatment, follow-up of 1 year, the treatment group, the recurrence rate was 5.0%, the control group was
25.0%, the recurrence rate of the treatment group was significantly lower than the control group, compared to obvious differences were
statistically significant (P <0.05 ). Through observation, bladder irritation treatment group, bone marrow suppression, urethral stricture
overall incidence of adverse reactions was significantly less than the control group, both statistically significant (P <0.05).Conclusion:Compared with gemcitabine, the Star THP intravesical prevention of recurrence of superficial bladder cancer have a good effect, fewer
adverse reactions, in accordance with the actual situation on the clinical needs of patients to choose a different infusion drugs. |
